The National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech program has established the Independent Test Assessment Program (ITAP) in order to accelerate regulatory review and availability of high-quality, accurate, and reliable diagnostic tests.
Funding Opportunity Announcements
Hepatitis C Virus (HCV) RNA Point-of-Care (POC) Diagnostics
ITAP is not presently accepting applications for Hepatitis C Virus (HCV) RNA point-of-care diagnostic tests. Applications that were submitted prior to March 12, 2023 that meet all the previous eligibility criteria will be reviewed. Any future opportunities will be announced on the NIBIB website.
COVID-19 Tests
The National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative has established the Independent Test Assessment Program (ITAP) in order to accelerate regulatory review and availability of high-quality, accurate, and reliable over-the-counter COVID-19 tests to the public. ITAP is not presently accepting new applications for COVID-19 tests.
Multiplex Point-of-Care (POC) Diagnostic Tests
ITAP is not presently accepting new applications for multiplex point-of-care diagnostic tests. Applications that were submitted by December 16, 2022 that meet all the previous eligibility criteria will be reviewed.
Mpox Virus Tests
ITAP is not presently accepting new applications for mpox (formerly monkeypox) virus tests. Applications that were submitted prior to October 17, 2022 that meet all the previous eligibility criteria will be reviewed. Any future opportunities will be announced on the NIBIB website.
Emergency Use Authorization
COVID-19 Tests with Emergency Use Authorization
ITAP COVID-19 Tests Produced Per Month
Data Updated: 03/01/23
Description: Number of tests produced per month are manufacturing capability and includes over the counter (OTC) tests in the Independent Test Assessment Program (ITAP).
Mpox Tests with Emergency Use Authorization
Inquiries
Send inquiries to itapnibib@mail.nih.gov
Related News
